Ken Fisher’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.55M Sell
11,150
-13,285
-54% -$1.86M ﹤0.01% 621
2025
Q4
$3M Sell
24,435
-1,617
-6% -$197K ﹤0.01% 514
2025
Q3
$2.89M Buy
26,052
+15,352
+143% +$1.74M ﹤0.01% 531
2025
Q2
$1.19M Buy
10,700
+3,750
+54% +$399K ﹤0.01% 671
2025
Q1
$779K Sell
6,950
-3,656
-34% -$377K ﹤0.01% 723
2024
Q4
$980K Buy
10,606
+1,656
+19% +$149K ﹤0.01% 661
2024
Q3
$750K Sell
8,950
-4,254
-32% -$325K ﹤0.01% 696
2024
Q2
$906K Buy
13,204
+110
+0.8% +$7.34K ﹤0.01% 694
2024
Q1
$959K Buy
13,094
+788
+6% +$60.6K ﹤0.01% 693
2023
Q4
$997K Sell
12,306
-1,376
-10% -$107K ﹤0.01% 691
2023
Q3
$1.03M Sell
13,682
-26
-0.2% -$2K ﹤0.01% 739
2023
Q2
$1.06M Buy
13,708
+2,105
+18% +$168K ﹤0.01% 767
2023
Q1
$963K Sell
11,603
-1,281
-10% -$106K ﹤0.01% 780
2022
Q4
$1.11M Sell
12,884
-761
-6% -$60.3K ﹤0.01% 751
2022
Q3
$842K Buy
13,645
+1,880
+16% +$119K ﹤0.01% 699
2022
Q2
$727K Buy
11,765
+5,397
+85% +$334K ﹤0.01% 660
2022
Q1
$379K Sell
6,368
-1,884
-23% -$120K ﹤0.01% 776
2021
Q4
$599K Buy
8,252
+340
+4% +$23.4K ﹤0.01% 731
2021
Q3
$553K Sell
7,912
-1,091
-12% -$76.6K ﹤0.01% 713
2021
Q2
$620K Sell
9,003
-260
-3% -$17.4K ﹤0.01% 685
2021
Q1
$599K Sell
9,263
-101
-1% -$6.51K ﹤0.01% 677
2020
Q4
$546K Buy
9,364
+2,667
+40% +$161K ﹤0.01% 694
2020
Q3
$423K Buy
6,697
+3,213
+92% +$223K ﹤0.01% 687
2020
Q2
$268K Sell
3,484
-1,390
-29% -$107K ﹤0.01% 739
2020
Q1
$364K Sell
4,874
-500,913
-99% -$34.6M ﹤0.01% 655
2019
Q4
$32.9M Sell
505,787
-146,467
-22% -$9.54M 0.03% 223
2019
Q3
$41.3M Buy
652,254
+29,203
+5% +$1.91M 0.05% 214
2019
Q2
$42.1M Buy
623,051
+7,250
+1% +$477K 0.05% 219
2019
Q1
$40M Buy
615,801
+18,041
+3% +$1.2M 0.05% 213
2018
Q4
$37.4M Buy
597,760
+38,205
+7% +$2.67M 0.05% 209
2018
Q3
$43.2M Sell
559,555
-13
-0% -$982 0.05% 215
2018
Q2
$39.6M Buy
559,568
+31,109
+6% +$2.2M 0.05% 223
2018
Q1
$39.8M Buy
528,459
+85,685
+19% +$6.81M 0.05% 224
2017
Q4
$31.7M Sell
442,774
-26,626
-6% -$2.02M 0.04% 241
2017
Q3
$38M Buy
469,400
+9,245
+2% +$707K 0.05% 217
2017
Q2
$32.6M Buy
460,155
+8,521
+2% +$567K 0.05% 228
2017
Q1
$30.7M Sell
451,634
-3,862
-0.8% -$272K 0.05% 219
2016
Q4
$32.6M Buy
455,496
+10,967
+2% +$815K 0.06% 209
2016
Q3
$35.2M Sell
444,529
-1,964
-0.4% -$160K 0.06% 201
2016
Q2
$38.5M Sell
446,493
-40,537
-8% -$3.6M 0.07% 178
2016
Q1
$47.9M Sell
487,030
-76,887
-14% -$6.93M 0.09% 152
2015
Q4
$57.1M Buy
563,917
+1,526
+0.3% +$159K 0.11% 131
2015
Q3
$55.2M Sell
562,391
-229,239
-29% -$25.5M 0.12% 133
2015
Q2
$92.7M Buy
791,630
+2,015
+0.3% +$220K 0.18% 95
2015
Q1
$77.5M Buy
789,615
+18,114
+2% +$1.84M 0.15% 108
2014
Q4
$72.7M Buy
771,501
+8,078
+1% +$835K 0.15% 111
2014
Q3
$81.3M Sell
763,423
-212,060
-22% -$20.8M 0.17% 86
2014
Q2
$80.9M Buy
975,483
+373,725
+62% +$29.1M 0.17% 94
2014
Q1
$42.6M Sell
601,758
-331,497
-36% -$26M 0.1% 157
2013
Q4
$70.1M Sell
933,255
-44,103
-5% -$3.07M 0.16% 111
2013
Q3
$61.4M Sell
977,358
-60,010
-6% -$3.59M 0.15% 111
2013
Q2
$53.2M Buy
+1,037,368
New +$54.1M 0.14% 121

Other funds holding GILD

Ken Fisher's GILD Position: Q1 2026 in Review

Ken Fisher reduced its Gilead Sciences (GILD) stake by 54% in Q1 2026, selling an estimated $1.86M and leaving 11,150 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #621.

Ken Fisher first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $92.7M in Q2 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Ken Fisher held 11,150 shares of Gilead Sciences worth $1.55M as of Q1 2026.
  • Ken Fisher sold 13,285 Gilead Sciences shares in Q1 2026, an estimated $1.86M.
  • Gilead Sciences made up ﹤0.01% of Ken Fisher's portfolio in Q1 2026, its #621 holding.
  • Ken Fisher first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Ken Fisher's Gilead Sciences position peaked at $92.7M in Q2 2015.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.